How inebilizumab addresses key drivers of neuromyelitis optica spectrum disorder: an interview with Prof. Friedemann Paul & Kristina Patterson MD PhD

Neuromyelitis optica spectrum disorder (NMOSD) is a rare and devastating autoimmune disease characterized by inflammation of the spinal cord and optic nerves. Although there is currently no cure for NMOSD, the past few years have seen the development of drugs, such as inebilizumab, that are able to treat the disease.

In this video interview, filmed at ECTRIMS 2022 Congress (26–28 October; Amsterdam, the Netherlands), we speak with Professor Friedemann Paul (Clinical and Experimental Neuroimmunology, NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitaetsmedizin Berlin; Germany) and Kristina Patterson (MD, PhD, Medical Director, Neuroimmunology at Horizon; IL, USA) about the clinical evidence for inebilizumab, including new data presented at ECTRIMS, for the treatment of people living with NMOSD, a rare and devastating autoimmune disease.